Skip NavigationSkip to Content

The G-protein-coupled chemoattractant receptor Fpr2 exacerbates neuroglial dysfunction and angiogenesis in diabetic retinopathy

  1. Author:
    Yu, Ying
    Xue, Shengding
    Chen,Keqiang
    Le, Yingying
    Zhu, Rongrong
    Wang, Shiyi
    Liu, Shuang
    Cheng, Xinliang
    Guan, Huaijin
    Wang,Jiming
    Chen, Hui
  2. Author Address

    Eye Institute Affiliated Hospital of Nantong University Nantong China., Cancer and Inflammation Program Center for Cancer Research National Cancer Institute at Frederick Frederick MD USA., CAS Key Laboratory of Nutrition, Metabolism and Food Safety Shanghai Institute of Nutrition and Health Chinese Academy of Sciences Shanghai China.,
    1. Year: 2020
    2. Date: Oct
    3. Epub Date: 2020 09 15
  1. Journal: FASEB bioAdvances
    1. 2
    2. 10
    3. Pages: 613-623
  2. Type of Article: Article
  1. Abstract:

    Diabetic retinopathy (DR) as a retinal neovascularization-related disease is one of the leading causes of irreversible blindness in patients. The goal of this study is to determine the role of a G-protein-coupled chemoattractant receptor (GPCR) FPR2 (mouse Fpr2) in the progression of DR, in order to identify novel therapeutic targets. We report that Fpr2 was markedly upregulated in mouse diabetic retinas, especially in retinal vascular endothelial cells, in associated with increased number of activated microglia and Müller glial cells. In contrast, in the retina of diabetic Fpr2-/- mice, the activation of vascular endothelial cells and glia was attenuated with reduced production of proinflammatory cytokines. Fpr2 deficiency also prevented the formation of acellular capillary during diabetic progression. Furthermore, in oxygen-induced retinopathy (OIR) mice, the absence of Fpr2 was associated with diminished neovasculature formation and pathological vaso-obliteration region in the retina. These results highlight the importance of Fpr2 in exacerbating the progression of neuroglial degeneration and angiogenesis in DR and its potential as a therapeutic target. © 2020 The Authors. FASEB BioAdvances published by the Federation of American Societies for Experimental Biology.

    See More

External Sources

  1. DOI: 10.1096/fba.2020-00034
  2. PMID: 33089077
  3. PMCID: PMC7566047
  4. PII : FBA21162

Library Notes

  1. Fiscal Year: FY2020-2021
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel